More than 60 billion euros (£52 billion) has been wiped off the stock market value of Ozempic and Wegovy weight loss drug firm Novo Nordisk after it warned over sales and profits as competition ramps up in the US.
Novo Nordish saw shares plunge by over a fifth following the alert, with the group slashing its guidance for sales growth to 8% to 14%, down from the previous range of 13% to 21% given in May.
